Baird raised the firm’s price target on Editas Medicine (EDIT) to $6 from $4 and keeps an Outperform rating on the shares. The company’s Q2 results were inline with expectations as it continues to advance its in vivo editing programs, the analyst tells investors in a research note. The firm believes the announcement of a lead candidate in September could drive interest in the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT: